Status not kept up to date
Endoscopic Robot-Assisted Simple Enucleation Versus Standard Robot-Assisted Partial Nephrectomy in the Treatment of T1 Renal Cell Carcinoma
NCT03624673 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Updated 6 April 2021
- What is being tested
- endoscopic robot-assisted simple enucleation; standard robot-assisted partial nephrectomy
- For
- Renal Cell Carcinoma
- Kind of study
- Tests a treatment or device on volunteers. No drug phase (a device or procedure study).
- Who can join
- Ages 18 years to 80 years. About 380 people. The full rules are on the registry page.
- Where
- China
- When
- Starts or started 11 Oct 2018, ends Oct 2025. Registered 10 Aug 2018.
- Results
- None posted yet.
In the researchers' words
This is a non-inferiority, randomized controlled trial to compare the peri-operative, renal functional and oncologic outcomes of endoscopic robot-assisted simple enucleation(ERASE) and standard robot-assisted partial nephrectomy(RAPN) in the treatment of T1 renal cell carcinoma.
Sites
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNanjing, Jiangsu, China